Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy-A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study.
adjuvant chemotherapy
biomarkers
breast cancer
tumor-infiltrating lymphocytes
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Nov 2022
16 Nov 2022
Historique:
received:
26
08
2022
revised:
01
11
2022
accepted:
11
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
27
11
2022
Statut:
epublish
Résumé
Tumor-infiltrating lymphocytes (TILs) contribute to breast cancer (BC) prognosis. We investigated the prognostic impact of CD8+ TILs in patients with early breast cancer treated with adjuvant chemotherapy in a large observational clinical trial. Along with a 10 year follow-up, considering the efficacy and safety, we report the results of the translational part of our study. We examined the patients' tumors for total (t), stromal (s), and intratumoral (i) CD8 lymphocyte density (counts/mm
Identifiants
pubmed: 36428728
pii: cancers14225635
doi: 10.3390/cancers14225635
pmc: PMC9688913
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Hellenic Cooperative Oncology Group
ID : N/A
Organisme : Hellenic Society for Medical Oncology
ID : N/A
Références
Lab Invest. 2006 Mar;86(3):231-45
pubmed: 16446705
J Natl Cancer Inst. 2009 May 20;101(10):736-50
pubmed: 19436038
N Engl J Med. 2008 Apr 17;358(16):1663-71
pubmed: 18420499
Rom J Morphol Embryol. 2009;50(4):651-5
pubmed: 19942961
PLoS One. 2017 Feb 6;12(2):e0170634
pubmed: 28166544
J Clin Oncol. 2005 Jun 1;23(16):3686-96
pubmed: 15897552
PLoS One. 2014 Apr 17;9(4):e95475
pubmed: 24743335
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Cancer Immunol Immunother. 2020 Aug;69(8):1549-1564
pubmed: 32303794
Mod Pathol. 2010 May;23 Suppl 2:S60-4
pubmed: 20436504
Cancer Res. 2010 Nov 1;70(21):8368-77
pubmed: 20940398
Breast Cancer Res Treat. 2016 Jun;157(2):363-371
pubmed: 27155668
J Clin Oncol. 2005 Oct 20;23(30):7483-90
pubmed: 16234514
BMC Cancer. 2018 Feb 3;18(1):129
pubmed: 29394917
Ann Oncol. 2005 Oct;16(10):1569-83
pubmed: 16148022
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
Oncotarget. 2017 Aug 12;8(48):83986-83994
pubmed: 29137398
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
J Clin Oncol. 2010 Jun 10;28(17):2874-80
pubmed: 20458045
J Natl Cancer Inst. 2010 Dec 15;102(24):1845-54
pubmed: 21098761
Nat Med. 2018 Jul;24(7):986-993
pubmed: 29942092
Oncotarget. 2016 Jan 26;7(4):5074-87
pubmed: 26506242
J Clin Oncol. 2003 Apr 15;21(8):1431-9
pubmed: 12668651
J Clin Invest. 2022 Jan 18;132(2):
pubmed: 34813506
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25
pubmed: 29024776
Breast Cancer Res. 2015 Sep 04;17:124
pubmed: 26341640
Ann Oncol. 2014 Aug;25(8):1544-50
pubmed: 24608200
Ann Oncol. 2005 Nov;16(11):1762-71
pubmed: 16148021
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
Transl Oncol. 2019 Mar;12(3):585-595
pubmed: 30682679
Ther Adv Med Oncol. 2020 Feb 27;12:1758835919888999
pubmed: 32158505
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
J Clin Oncol. 2008 Oct 20;26(30):4869-74
pubmed: 18794552
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Mol Sci. 2020 Sep 22;21(18):
pubmed: 32971948
Ann Oncol. 2014 Aug;25(8):1536-43
pubmed: 24915873
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
J Natl Cancer Inst. 2008 Jun 4;100(11):805-14
pubmed: 18505968
Breast Cancer. 2017 Jan;24(1):3-15
pubmed: 27138387
J Clin Oncol. 2011 Nov 10;29(32):4273-8
pubmed: 21990413
Cancers (Basel). 2021 Jun 18;13(12):
pubmed: 34207414
J Clin Oncol. 2011 Mar 1;29(7):859-67
pubmed: 21189395
PLoS One. 2016 Apr 13;11(4):e0152500
pubmed: 27073890
PLoS One. 2012;7(6):e37946
pubmed: 22679488
Cancer Treat Rev. 2010 Nov;36 Suppl 3:S80-6
pubmed: 21129616
Clin Cancer Res. 2008 Aug 15;14(16):5220-7
pubmed: 18698040
Nat Med. 2021 Aug;27(8):1410-1418
pubmed: 34385708
Hum Cell. 2020 Oct;33(4):930-937
pubmed: 32507979
Oncoimmunology. 2012 Nov 1;1(8):1239-1247
pubmed: 23243587
Ann Oncol. 2008 May;19(5):853-60
pubmed: 18042835
BMC Cancer. 2014 Jul 15;14:515
pubmed: 25026897
Acta Oncol. 2018 Jan;57(1):74-82
pubmed: 29168430
Nat Rev Cancer. 2020 Apr;20(4):218-232
pubmed: 32024970
Clin Cancer Res. 2015 Nov 15;21(22):5047-56
pubmed: 26567364
J Clin Oncol. 2007 Jan 1;25(1):118-45
pubmed: 17159189
J Natl Cancer Inst. 2016 Oct 13;109(1):
pubmed: 27737921
Breast J. 2012 May-Jun;18(3):261-6
pubmed: 22583196
Br J Cancer. 2022 Sep;127(4):695-703
pubmed: 35610366
Oncogene. 2010 Feb 25;29(8):1093-102
pubmed: 19946335
N Engl J Med. 2005 Oct 20;353(16):1659-72
pubmed: 16236737
Curr Treat Options Oncol. 2012 Jun;13(2):230-9
pubmed: 22410709
Breast Cancer Res Treat. 2012 Apr;132(2):609-19
pubmed: 22187126
Sci Rep. 2020 Nov 18;10(1):20100
pubmed: 33208857
Indian J Med Res. 2014 Sep;140(3):361-9
pubmed: 25366203
Breast Cancer Res. 2012 Mar 15;14(2):R48
pubmed: 22420471
J Clin Oncol. 2010 Jun 1;28(16):2784-95
pubmed: 20404251
N Engl J Med. 2011 Oct 6;365(14):1273-83
pubmed: 21991949